Synthetic hirudin-derived peptide that directly inhibits thrombin. Parent drug (Angiomax) FDA-approved for anticoagulation in PCI. The peptide fragment retains thrombin-binding properties. Research applications in angiogenesis and tissue healing.
Directly inhibits thrombin (factor IIa) via binding to both the active site and exosite 1. Prevents fibrin formation and thrombus growth. May modulate angiogenic signaling through thrombin pathway.
Research protocols only. Not established for clinical use as peptide supplement.
Research use only.